Therèse Heinonen

1.6k total citations
39 papers, 1.2k citations indexed

About

Therèse Heinonen is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Therèse Heinonen has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Surgery, 13 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Therèse Heinonen's work include Lipoproteins and Cardiovascular Health (23 papers), Cardiac Imaging and Diagnostics (11 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers). Therèse Heinonen is often cited by papers focused on Lipoproteins and Cardiovascular Health (23 papers), Cardiac Imaging and Diagnostics (11 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (10 papers). Therèse Heinonen collaborates with scholars based in Canada, United States and Switzerland. Therèse Heinonen's co-authors include Jean‐Claude Tardif, Donald M. Black, Philippe L. L’Allier, David G. Orloff, Réda Ibrahim, Peter Libby, Olivier F. Bertrand, Linda Shurzinske, Jean‐Claude Tardif and Richard McLain and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Therèse Heinonen

37 papers receiving 1.1k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Therèse Heinonen 691 334 242 221 197 39 1.2k
Tsuyoshi Nozue 672 1.0× 279 0.8× 112 0.5× 293 1.3× 154 0.8× 76 1.1k
Nick S. Nurmohamed 534 0.8× 377 1.1× 145 0.6× 185 0.8× 167 0.8× 68 1.1k
Clare Neuwirth 1.2k 1.8× 468 1.4× 255 1.1× 342 1.5× 215 1.1× 40 1.7k
Gabriel P. Lasala 690 1.0× 184 0.6× 266 1.1× 388 1.8× 94 0.5× 14 1.0k
Ping Qing 654 0.9× 437 1.3× 112 0.5× 283 1.3× 69 0.4× 70 1.2k
Adam W. Grasso 411 0.6× 148 0.4× 261 1.1× 249 1.1× 138 0.7× 6 883
Adam Oesterle 498 0.7× 409 1.2× 234 1.0× 100 0.5× 69 0.4× 29 1.2k
Stephen W. Halpern 1.0k 1.5× 440 1.3× 229 0.9× 674 3.0× 202 1.0× 8 1.5k
M van Linde-Sibenius Trip 706 1.0× 401 1.2× 116 0.5× 480 2.2× 87 0.4× 8 1.2k
John C. Cedarholm 678 1.0× 586 1.8× 74 0.3× 178 0.8× 255 1.3× 7 1.1k

Countries citing papers authored by Therèse Heinonen

Since Specialization
Citations

This map shows the geographic impact of Therèse Heinonen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Therèse Heinonen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Therèse Heinonen more than expected).

Fields of papers citing papers by Therèse Heinonen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Therèse Heinonen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Therèse Heinonen. The network helps show where Therèse Heinonen may publish in the future.

Co-authorship network of co-authors of Therèse Heinonen

This figure shows the co-authorship network connecting the top 25 collaborators of Therèse Heinonen. A scholar is included among the top collaborators of Therèse Heinonen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Therèse Heinonen. Therèse Heinonen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Renaud, Jennifer M., François Harel, Therèse Heinonen, et al.. (2020). Site qualification and clinical interpretation standards for 99mTc-SPECT perfusion imaging in a multi-center study of MITNEC (Medical Imaging Trials Network of Canada). Journal of Nuclear Cardiology. 28(6). 2712–2725. 2 indexed citations
2.
Tardif, Jean‐Claude, Marie‐Pierre Dubé, Marc A. Pfeffer, et al.. (2020). Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib. American Heart Journal. 222. 157–165. 18 indexed citations
3.
Black, Donald M., Darren Bentley, Sunny Chapel, et al.. (2018). Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib. Clinical Pharmacokinetics. 57(11). 1359–1367. 13 indexed citations
4.
Tardif, Jean‐Claude, Jean-François Tanguay, Scott Wright, et al.. (2013). Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non–ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology. 61(20). 2048–2055. 166 indexed citations
5.
Heinonen, Therèse, et al.. (2012). Cardiovascular biomarkers and surrogate end points: key initiatives and clinical trial challenges. Expert Review of Cardiovascular Therapy. 10(8). 989–994. 2 indexed citations
6.
Tardif, Jean‐Claude, J. David Spence, Therèse Heinonen, et al.. (2012). Atherosclerosis Imaging and the Canadian Atherosclerosis Imaging Network. Canadian Journal of Cardiology. 29(3). 297–303. 23 indexed citations
7.
Pressacco, Joséphine, Jacques Lespérance, Colin Berry, et al.. (2009). Evaluation of coronary atheroma by 64-slice multidetector computed tomography: Comparison with intravascular ultrasound and angiography. Canadian Journal of Cardiology. 25(11). 641–647. 15 indexed citations
8.
Heinonen, Therèse, David D. Waters, Peter Libby, & Jean‐Claude Tardif. (2009). A winter’s tale: Report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium. Canadian Journal of Cardiology. 25(9). 527–532. 1 indexed citations
9.
Tardif, Jean‐Claude, Therèse Heinonen, & Stéphane Noble. (2008). High-density lipoprotein/apolipoprotein A-I infusion therapy. Current Atherosclerosis Reports. 11(1). 58–63. 32 indexed citations
10.
Trumbo, Paula R., et al.. (2008). Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease. Nutrition Reviews. 66(2). 76–81. 10 indexed citations
11.
Tardif, Jean‐Claude, Michel Carrier, David E. Kandzari, et al.. (2007). Effects of pyridoxal-5′-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: Results of the MEND-CABG randomized study. Journal of Thoracic and Cardiovascular Surgery. 133(6). 1604–1611.e1. 18 indexed citations
12.
Dorbala, Sharmila, et al.. (2006). Coronary vasodilator reserve and Framingham risk scores in subjects at risk for coronary artery disease. Journal of Nuclear Cardiology. 13(6). 761–767. 27 indexed citations
13.
Tardif, Jean‐Claude, Jean Grégoire, Philippe L. L’Allier, et al.. (2006). Effect of Atherosclerotic Regression on Total Luminal Size of Coronary Arteries as Determined by Intravascular Ultrasound. The American Journal of Cardiology. 98(1). 23–27. 19 indexed citations
14.
Mishra, Rakesh, et al.. (2005). Quantitative relation between hemodynamic changes during intravenous adenosine infusion and the magnitude of coronary hyperemia. Journal of the American College of Cardiology. 45(4). 553–558. 36 indexed citations
15.
Luostarinen, Liisa, et al.. (2005). Diagnostic lumbar puncture. Comparative study between 22–gauge pencil point and sharp bevel needle. The Journal of Headache and Pain. 6(5). 400–404. 27 indexed citations
16.
Raal, Frederick J., et al.. (2003). Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis. 171(2). 273–279. 36 indexed citations
17.
Tardif, Jean‐Claude, Jean Grégoire, Jacques Lespérance, et al.. (2002). Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial. American Heart Journal. 144(4). 589–596. 33 indexed citations
18.
Heinonen, Therèse. (2002). Acyl coenzyme A:cholesterol acyltransferase inhibition: potential atherosclerosis therapy or springboard for other discoveries?. Expert Opinion on Investigational Drugs. 11(11). 1519–1527. 10 indexed citations
19.
Raal, Frederick J., Anuradha S. Pappu, D. Roger Illingworth, et al.. (2000). Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis. 150(2). 421–428. 73 indexed citations
20.
Alaupovic, Petar, Therèse Heinonen, Linda Shurzinske, & Donald M. Black. (1997). Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis. 133(1). 123–133. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tsuyoshi Nozue Breakdown of academic impact, for papers by Nick S. Nurmohamed Breakdown of academic impact, for papers by Clare Neuwirth Breakdown of academic impact, for papers by Gabriel P. Lasala Breakdown of academic impact, for papers by Ping Qing Breakdown of academic impact, for papers by Adam W. Grasso Breakdown of academic impact, for papers by Adam Oesterle Breakdown of academic impact, for papers by Stephen W. Halpern Breakdown of academic impact, for papers by M van Linde-Sibenius Trip Breakdown of academic impact, for papers by John C. Cedarholm
Rankless by CCL
2026